公司概述
Co-Diagnostics, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it develops, manufactures, and sells reagents for diagnostic tests that detect and analyze nucleic acid molecules in the United States and internationally. The company utilizes its proprietary Co-Dx PCR platform to execute its business strategy across these global markets. In terms of scale, the entity manages a market capitalization of $5.19 million and employs 115 individuals to support its operations. With annual revenue recorded at $622,489, the company operates as a micro-cap enterprise, indicating a relatively small position in the broader medical diagnostics landscape where valuation metrics often reflect early-stage growth potential rather than established market dominance.
财务健康
The company reported trailing twelve-month revenue of $622,489, yet it recorded a net income of $-46,895,936 and an EBITDA of $-30,176,544, revealing a significant structural gap where operating expenses and costs far exceed total revenue generation. The net loss is approximately 75 times the magnitude of the reported revenue, suggesting a cost structure where fixed overheads or R&D expenditures are not being covered by current sales volumes. Free cash flow stands at $-19,684,820, which indicates that the company is currently consuming cash reserves to fund its operations and strategic initiatives rather than generating liquidity for shareholders or debt repayment. Gross margin is reported at 64.3%, indicating that the company retains a substantial portion of revenue after cost of goods sold, yet this does not translate to profitability at the operating level. Operating margin is listed at -2902.3% and profit margin at 0.0%, figures that highlight severe operational inefficiencies or high one-time costs relative to the tiny revenue base. The balance sheet holds $11.88 million in cash against $1.24 million in debt, resulting in a debt-to-equity ratio of 5.99, which presents a leveraged profile despite the substantial cash cushion available to service obligations. The current ratio is 3.87, indicating a conservative short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer against immediate solvency risks. Return on equity is -125.9% and return on assets is -44.3%, metrics that reveal management has yet to generate positive returns on the capital invested in the business, reflecting the challenges of scaling a loss-making medical device venture.
估值评估
Valuation metrics for Co-Diagnostics present a complex picture given the negative earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -0.12, implying that the market is pricing the stock based on expectations of future earnings recovery rather than current profitability. The price-to-book ratio is 0.15, indicating that the market values the company at significantly less than its book value, which often suggests a deep discount or specific risks associated with the asset base. Alternative valuation multiples such as the price-to-sales ratio of 8.33 and an EV/EBITDA of 0.18 are utilized instead of traditional earnings-based metrics to assess the company's worth relative to its sales and enterprise value. The stock trades between a 52-week high of $46.50 and a 52-week low of $1.35, placing the current price at a point where the valuation is heavily influenced by speculative factors rather than fundamental earnings power. With a beta of 1.43, the stock exhibits price volatility that is significantly higher than the broader market, meaning that price movements are expected to be amplified relative to general market swings.
Growth & Income
Revenue growth year-over-year is 76.7%, while earnings growth is N/A due to the absence of positive net income, indicating that top-line expansion is currently decoupled from bottom-line profitability as the company invests heavily in operations. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a strategy where all available earnings and cash flows are retained and reinvested into the business to support product development and market expansion rather than being distributed to shareholders. The absence of dividend payments underscores the growth-oriented nature of the firm, prioritizing capital allocation toward operational scaling over income generation for investors. Overall, the growth and income profile is characterized by high revenue expansion coupled with significant losses and no dividend distribution, typical of early-stage medical device companies attempting to establish market share.